You are here

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
03. Endometrial cancer
1103 Combinatory analysis of CfDNA and CtDNA as a predictive and follow up tool to improve endometrial cancer management
  1. Carlos Casas-Arozamena1,2,3,
  2. Alexandra Cortegoso4,
  3. Alicia Abalo1,
  4. Cristian Pablo Moiola5,
  5. Efigenia Arias6,
  6. Victoria Sampayo6,
  7. Ana Vilar6,
  8. Juan Cueva4,
  9. Silvia Cabrera5,
  10. Eva Diaz7,
  11. Eva Colás3,5,
  12. Antonio Gil-Moreno3,5,
  13. Gema Moreno-Bueno3,7,8,
  14. Miguel Abal1,3 and
  15. Laura Muinelo-Romay1,2,3
  1. 1Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706, Santiago De Compostela, Spain
  2. 2University of Santiago de Compostela (USC), Praza do Obradoiro, 0, 15705, Santiago de Compostela, Spain
  3. 3Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
  4. 4Department of Medical Oncology, University Clinical Hospital of Santiago de Compostela, University of Santiago de Compostela (USC), 15706, Santiago De Compostela, Spain
  5. 5Biomedical Research Group in Gynecology, Vall Hebron Research Institute (VHIR), Universitat Autonoma de Barcelona, 119–129 Pg. Vall d’Hebron, 08035, Barcelona, Spain
  6. 6Department of Gynecology, University Hospital of Santiago de Compostela (SERGAS), Trav. Choupana s/n, 15706, Santiago De Compostela, Spain
  7. 7Foundation MD Anderson International, C/Gómez Hemans 2, 28033, Madrid, Spain
  8. 8Biochemistry Department, Medicine Faculty, Universidad Autónoma de Madrid (UAM), C/Arturo Dupurier 4, 28029, Madrid, Spain

Abstract

Introduction/Background Minimally invasive biomarkers allow for the dynamic characterization of the disease. In the past years, there has been a rise on advanced endometrial cancers (EC) patients resulting in an increase on the mortality rates. This clinical paradigm highlights the need to find prognostic biomarkers that helps to identify those patients with worse clinical prognosis.

Methodology Plasma samples and the uterine aspirate (UA) from 148 patients with EC were collected in different hospitals within Spain at baseline and throughout the course of the disease (n=120). Total cfDNA was isolated from all plasma samples and analysed for the presence of ctDNA based on the mutational profile found on the UA.

Results High levels of cfDNA and detectable levels of ctDNA at baseline correlate with poor prognosis, in both PFS (Log-rank test p-value<0.0001; HR=10.80; 95% CI [5.20–23.20]) and OS (Log-rank test p-value<0.0001; HR=10.20; 95% CI [4.14–25.30]) (Figure 1A-B). Importantly, this approach remains clinically significant when stratifying patients based on histology or grade; highlighting its value to identify patients with poor prognosis. Moreover, longitudinal analyses of cfDNA and ctDNA proved to be a powerful asset to identify patients undergoing PD, since ctDNA presence was detected months prior to the arisen of any clinical evidence of progression (Figure C-D).

Conclusion High levels of cfDNA and detectable levels of ctDNA at baseline correlate with poor prognosis. Additionally, the longitudinal ctDNA monitoring allowed for the early identification of recurrences. Implementation of cfDNA/ctDNA analyses into the clinic could improve the management of the EC patients.

Disclosures The authors declare no conflict of interests.

Abstract 1103 Figure 1
Abstract 1103 Figure 1

https://doi.org/10.1136/ijgc-2024-ESGO.431

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.